Latest Ratios: P/E Ratio 35.5x · EV/EBITDA 4.9x · ROE 4.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $967M | $1.8B | $2.7B | $1.9B | $13.4B | $11.1B | — | — |
| Enterprise Value | $848M | $765M | $1.9B | $2.8B | $1.9B | $13.2B | $10.8B | — | — |
| P/E Ratio → | 35.52 | 31.77 | 111.24 | — | — | — | — | — | — |
| P/S Ratio | 1.32 | 1.21 | 2.30 | 3.66 | 2.51 | 17.97 | 20.12 | — | — |
| P/B Ratio | 1.76 | 1.57 | 2.52 | 3.61 | 2.36 | 16.11 | 15.58 | — | — |
| P/FCF | 6.39 | 5.89 | 16.06 | 33.31 | 21.01 | 92.84 | 116.01 | — | — |
| P/OCF | 6.26 | 5.76 | 9.92 | 19.88 | 13.11 | 74.94 | 84.37 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.96 | 2.42 | 3.72 | 2.46 | 17.65 | 19.64 | — | — |
| EV / EBITDA | 4.91 | 4.43 | 14.17 | 34.56 | 33.69 | 274.47 | — | — | — |
| EV / EBIT | 9.69 | 7.72 | 22.74 | 2411.66 | 171.07 | 977.30 | — | — | — |
| EV / FCF | — | 4.65 | 16.90 | 33.78 | 20.57 | 91.18 | 113.22 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8% | 92.8% | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% | 96.4% | 97.6% |
| Operating Margin | 11.0% | 11.0% | 8.3% | -3.6% | 0.2% | 1.8% | -50.1% | 36.0% | 31.0% |
| Net Profit Margin | 3.8% | 3.8% | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% | 17.0% | 17.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 4.5% | 2.2% | -1.1% | -4.0% | -3.3% | -41.3% | — | — |
| ROA | 2.2% | 2.2% | 1.1% | -0.6% | -2.0% | -1.6% | -31.2% | 18.8% | 13.9% |
| ROIC | 10.6% | 10.6% | 6.1% | -2.6% | 0.2% | 1.9% | -983.6% | — | — |
| ROCE | 7.2% | 7.2% | 4.8% | -1.8% | 0.1% | 0.9% | -30.8% | 42.9% | 25.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.75 | 0.93 | 0.88 | 0.84 | 0.99 | — | — |
| Debt / EBITDA | 0.34 | 0.34 | 4.01 | 8.82 | 12.82 | 14.65 | — | 4.64 | 8.30 |
| Net Debt / Equity | — | -0.33 | 0.13 | 0.05 | -0.05 | -0.29 | -0.37 | — | — |
| Net Debt / EBITDA | -1.17 | -1.17 | 0.70 | 0.48 | -0.72 | -4.98 | — | 4.47 | 7.90 |
| Debt / FCF | — | -1.23 | 0.84 | 0.47 | -0.44 | -1.65 | -2.79 | 8.83 | 16.45 |
| Interest Coverage | 2.33 | 2.33 | 1.59 | 0.02 | 0.32 | 0.57 | -9.87 | 2.67 | 3.36 |
Net cash position: cash ($262M) exceeds total debt ($60M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 | 2.59 | 4.40 |
| Quick Ratio | 2.61 | 2.61 | 5.32 | 7.12 | 12.05 | 13.42 | 18.24 | 2.59 | 4.40 |
| Cash Ratio | 1.06 | 1.06 | 3.62 | 5.49 | 9.92 | 11.60 | 16.32 | 0.78 | 2.08 |
| Asset Turnover | — | 0.57 | 0.57 | 0.47 | 0.48 | 0.46 | 0.37 | 1.00 | 0.79 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 107.98 | 74.09 | 77.86 | 57.93 | 61.90 | 64.49 | 52.20 | 48.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | 3074.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.8% | 3.1% | 0.9% | — | — | — | — | — | — |
| FCF Yield | 15.7% | 17.0% | 6.2% | 3.0% | 4.8% | 1.1% | 0.9% | — | — |
| Buyback Yield | 19.7% | 21.4% | 8.7% | 3.8% | 5.3% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 19.7% | 21.4% | 8.7% | 3.8% | 5.3% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $357M | $392M | $410M | $413M | $410M | $275M | $363M | $363M |
PBM Disintermediation and Regulatory Exposure
Based on current market data, GDRX trades at a forward P/E of 9.06, which, when compared to the broader healthcare information services sector, suggests that investors are pricing in a permanent deceleration in top-line growth rather than a temporary cyclical downturn in prescription transaction volumes.
The compression in valuation multiples appears to reflect a market transition from valuing the company as a high-growth marketplace to a mature, defensive utility. Investors should monitor whether the current forward P/E multiple provides a sufficient margin of safety given the structural risks associated with PBM-dependent revenue streams.
As reported in financial statements, GDRX's ROIC has struggled to gain traction, hovering at a modest 2.4% in 2026Q1, which indicates that the company's historical investments in platform expansion and acquisitions have yet to generate returns that meaningfully exceed the cost of capital.
The persistent gap between gross margins and return on capital highlights the heavy burden of operating expenses and marketing spend required to sustain the platform. This trend warrants further investigation into whether management can improve capital allocation efficiency without sacrificing the market share necessary to maintain its network effect.
According to recent SEC filings, the company's DSO has trended upward to 109 days in 2026Q1, suggesting that the timing of PBM settlements and transaction-related adjustments is creating significant friction in the cash conversion cycle compared to historical performance levels observed in previous fiscal years.
The lengthening of the collection cycle may indicate shifting leverage dynamics between GoodRx and its PBM partners. Investors should interpret this trend as a potential signal of reduced bargaining power, which could lead to further liquidity constraints if the trend toward longer payment cycles continues to persist.
Based on reported figures, the current ratio has contracted from 7.12 in 2023Q4 to 1.47 in 2026Q1, reflecting a deliberate strategy to utilize cash reserves for debt reduction while simultaneously navigating a more challenging environment for organic revenue generation and operational cash flow stability.
While the reduction in debt improves the balance sheet's long-term risk profile, the tightening liquidity position leaves less room for error in the event of a sudden regulatory or competitive shock. The company appears to be prioritizing a cleaner balance sheet over maintaining the high liquidity buffers seen during its earlier growth phase.
As indicated by forensic analysis of GAAP earnings, the P/E ratio is a highly misleading metric for GDRX because it fails to account for the significant non-cash impact of stock-based compensation, which consistently bridges the gap between reported net losses and positive operating cash flow.
Investors should instead focus on adjusted free cash flow or EBITDA-based metrics to gauge the company's true economic earning power. Relying on the P/E ratio risks overestimating the company's profitability by ignoring the recurring dilution and economic costs associated with the company's current compensation structure.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GDRX stock.
GoodRx Holdings, Inc.'s current P/E ratio is 35.5x. The historical average is 71.5x. This places it at the 50th percentile of its historical range.
GoodRx Holdings, Inc.'s current EV/EBITDA is 4.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.7x.
GoodRx Holdings, Inc.'s return on equity (ROE) is 4.5%. The historical average is -7.2%.
Based on historical data, GoodRx Holdings, Inc. is trading at a P/E of 35.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
GoodRx Holdings, Inc. has 92.8% gross margin and 11.0% operating margin. Operating margin between 10-20% is typical for established companies.
GoodRx Holdings, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.